CTNNB1 and neoplasm: Additionally, ctDNA, specifically CTNNB1 mutations, is a sensitive marker for tumor burden and treatment response [92], while SUA serves as a promising prognostic tool, correlating with advanced tumor stages and poor treatment responses [93].